Tg Therapeutics (TGTX) Cash from Investing Activities Growth (3y) (2014 - 2026)
Powered by 
Analysis
Tg Therapeutics (TGTX) Cash from Investing Activities Growth (3y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -44.69% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -39.73% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -246.81% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -53.57% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.84% |
| 10 | Tg Therapeutics | 7.97 Bn | 7.29 Bn | 199.14 Mn | -67.68% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -67.68% |
| Mar 31, 2026 | -16.94% |
| Dec 31, 2025 | -43.60% |
| Sep 30, 2025 | 159.65% |
| Jun 30, 2025 | -33.60% |
| Mar 31, 2025 | 33.34% |
| Dec 31, 2024 | 68.71% |
| Sep 30, 2024 | -145.48% |
| Jun 30, 2024 | 39.47% |
| Mar 31, 2024 | -162.10% |
| Dec 31, 2023 | 4.92% |
| Sep 30, 2023 | -59.10% |
| Jun 30, 2023 | 39.63% |
| Mar 31, 2023 | -84.24% |
| Dec 31, 2022 | 1,496.25% |
| Sep 30, 2022 | -308.07% |
| Jun 30, 2022 | 183.19% |
| Mar 31, 2022 | -237.60% |
| Dec 31, 2021 | 139.95% |
| Sep 30, 2021 | 53.89% |